ALTO-101 study for schizophrenia cognitive symptoms
Part of Mental health clinical trials.
This study tests an experimental medication called ALTO-101 for people with schizophrenia who also have cognitive impairment (memory or thinking problems). It aims to see if the drug can improve these symptoms while you continue your current antipsychotic treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Diagnosed with schizophrenia for at least one year.
- Has trouble with memory, attention, or thinking (cognitive impairment).
- On a stable dose of 1 to 2 antipsychotic medications for at least 8 weeks.
- No current major depression or other bipolar/schizoaffective disorder.
- Not taking clozapine, mood stabilizers, or daily benzodiazepines.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medication called LB-102 for people with acute (sudden worsening of) schizophrenia. It aims to see if the drug helps reduce symptoms like hallucinations or disorganized thinking.
This study tests a new treatment that may help with thinking and memory problems in people with schizophrenia. It is for people whose schizophrenia symptoms are stable and who are already on a steady medication.
This study tests a new combination medication (xanomeline/trospium) to see if it helps improve thinking and memory problems in people with schizophrenia. It lasts about a year, and participants continue their usual antipsychotic treatment.
This trial tests an experimental medication to reduce hallucinations and delusions in people who have Alzheimer's disease. It may help manage these symptoms and improve quality of life for patients and their caregivers.
This study tests a long-term medicine (ACP-204) for people with Alzheimer's disease who also have psychosis (hallucinations or delusions). If you took part in the earlier ACP-204 study, this open-label extension lets you continue receiving the medicine to see how well it works over time.
This trial tests a long-term treatment (ML-007C-MA) for people with Alzheimer's disease who have psychosis. It is for those who already completed an earlier study with the same drug and may benefit from continuing it. The goal is to see if ongoing treatment is helpful and safe.
Hear when a new Schizophrenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.